1. Pages
  2. Team

Behind The Great Team

Our Team

John Turchi, PhD

John Turchi, PhD

President, Co-founder and CSO
  • Professor and the Tom and Julie Wood Family Foundation Chair in Lung Cancer Research at Indiana University School of Medicine and Melvin and Bren Simon Cancer Center
  • Co-leader of the Indiana University Melvin and Bren Simon Cancer Center Experimental and Developmental Therapeutics Program
  • Author of over 90 papers on DNA repair and cancer.
  • NIH funded cancer research lab since 1995; $6MM to date and $3MM start Dec. 1
Katherine Pawelczak, Ph.D.

Katherine Pawelczak, Ph.D.

VP of Research
  • Manager, Dow Agro Sciences-Discovery
  • Industry experience in discovery and deployment of novel DNA repair centric biotechnology tools
  • Primary investigator on numerous SBIR awards through the NIH-NCI
Trent Carrier, Ph.D.

Trent Carrier

Member, BOD
  • Senior VP, Kiadis Pharmaceuticals
  • CEO, CytoSen Therapeutics
  • Independent Consultant, CT Biotechnologies
  • VP, Vaccine technology and engineering, Takeda Pharmaceuticals
  • Senior Director, Bioprocess Development and Cellular Medicine, Life Technologies
Nick Ball

Nick Ball

Member, BOD
  • Co-Founder and CFO Integral Technologies EVP and CFO Truevision, Inc.
  • Vice President Bank One Manager of Financial and Regulatory Reporting, VP of Accounting Services, Commercial Loan
  • Indiana University alumni
Robert Feltgen

Robert Feltgen

  • 20 years of experience in the healthcare sector and has held numerous positions in sales, marketing and management expanding the pharmaceutical, medical device, and capital equipment segments at leading healthcare companies including Smith Kline Beecham, Kos Pharmaceuticals, Merck, and Bausch & Lomb
Lawrence Einhorn

Lawrence Einhorn, MD

Lawrence Einhorn, MD Chair, Medical Advisory Board
  • Distinguished Professor of Medicine at the Indiana University School of Medicine and the Livestrong Endowed professor.
  • Member of the US National Academy of Sciences.
  • Past President of the American Society of Clinical Oncology.
  • Pioneered medical treatment that increased cure rates for germ cell tumors from less than 10% to nearly 95%.
  • Author of over 300 manuscripts and book chapters and recipient of numerous national and international awards.
Shadia Jalal

Shadia Jalal, MD

Chair, Medical Advisory Board
  • Associate Professor of Hematology/Oncology, Indiana University School of Medicine
  • Chief Scientific Office, Hoosier Cancer Research Network (HCRN)
  • Past Medical Director, IUSCC Clinical Trials Office
  • Member of the Experimental and Developmental Therapeutics group, IU School of Medicine
Jim Schulz

Jim Schulz

  • Director-CliftonLarsonAllen LLP
  • 25 years of business and industry experience in roles such as Chief Financial Officer and Director of Finance